Member Info for Investoradam

Hi Adam,

Thanks for your email. The interim analysis of the SG015 trial of SNG001 (the Company’s wholly-owned inhaled formulation of interferon beta) in COPD patients is ongoing and the Company intends to announce data from this trial imminently. Synairgen is discussing the rapid progression of SNG001 as a potential COVID-19 treatment with regulatory agencies and other key groups.

The Company will provide all other updates in due course, and as soon as it is practicable to do so.

Am I allowed to share that?

For any investors worried about the lack of information or an RNS why not email synergain investor relations. I did yesterday and got a response to all of my questions, Kris was very helpful,

Good luck with With your investments